Comparison of prostate-specific antigen adjusted for transition zone volume versus prostate-specific antigen density in predicting prostate cancer by transrectal ultrasonography
- Authors
- Sung, DJ; Cho, SB; Kim, YH; Oh, YW; Lee, NJ; Kim, JH; Chung, KB; Moon, DG
- Issue Date
- 5월-2004
- Publisher
- WILEY
- Keywords
- prostate; prostate neoplasms; ultrasonography
- Citation
- JOURNAL OF ULTRASOUND IN MEDICINE, v.23, no.5, pp.615 - 622
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF ULTRASOUND IN MEDICINE
- Volume
- 23
- Number
- 5
- Start Page
- 615
- End Page
- 622
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/124327
- DOI
- 10.7863/jum.2004.23.5.615
- ISSN
- 0278-4297
- Abstract
- Objective. Prostate-specific antigen is an excellent tumor marker, but it is not specific for prostate cancer. We evaluated the efficacy of prostate-specific antigen adjusted for transition zone volume calculated by transrectal ultrasonography in predicting prostate cancer in men with intermediate prostate-specific antigen levels of 4.1 to 10.0 ng/mL compared with prostate-specific antigen density. Methods. Between June 1998 and December 2001, prostate-specific antigen adjusted for transition zone volume was obtained from 131 patients who underwent ultrasonographically guided biopsies and had prostate-specific antigen of 4.1 to 10.0 ng/mL. Prostate-specific antigen density was calculated by dividing total serum prostate-specific antigen by total prostate volume, and total serum prostate-specific antigen was divided by transition zone volume to yield prostate-specific antigen adjusted for transition zone volume. This was compared with prostate-specific antigen density via receiver operating characteristic curves. Results. Of 131 patients, 34 (26%) had prostate cancer, and 97 (74%) had benign prostatic hyperplasia on pathologic examination. Total prostate volume was correlated with transition zone volume (P < 001) Mean prostate-specific antigen adjusted for transition zone volume and prostate-specific antigen density were 0.71 +/- 0.25 and 0.27 +/- 0.09 ng (.) mL(-1) (.) mL(-1) in patients with prostate cancer and 0.32 +/- 0.09 and 0.16 +/- 0.05 ng (.) mL(-1) (.) mL(-1) in patients with benign prostatic hyperplasia. With a cutoff value of 0.35 ng (.) mL(-1) (.) mL(-1), prostate-specific antigen adjusted for transition zone volume had sensitivity of 82% and specificity of 84%. Receiver operating characteristic curve analysis showed that prostate-specific antigen adjusted for transition zone volume predicted biopsy outcome significantly better than prostate-specific antigen density (P < .05). Conclusions. Prostate-specific antigen adjusted for transition zone volume is more accurate than prostate-specific antigen density in distinguishing prostate cancer from benign prostatic hyperplasia in men with intermediate serum prostate-specific antigen of 4.1 to 10.0 ng/mL. Determination of transition zone volume by transrectal ultrasonography may be helpful for predicting the probability of positive biopsy results.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.